Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors

The development of CDC25 phosphatase inhibitors is an interesting approach toward new antitumor agents, as CDC25 play keyroles in cell-cycle regulation and are overexpressed in numerous cancers. We previously reported a novel compound belonging to the thiazolopyrimidine family that inhibits CDC25 activity with an IC50 value of 13 µM and displays cytotoxic properties against HeLa […]

Read More
Learn More